Tag Archives: pediatric

GBT’s Oxbryta® Accepted by FDA for Priority Review for Pediatric Sickle Cell Disease

The FDA has accepted for Priority Review the supplemental New Drug Application (sNDA) for voxelotor (Oxbryta®) for the treatment of sickle cell disease in patients aged 4 to 11 years